Synaptic degeneration in Alzheimer disease
Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain
It is increasingly accepted that early cognitive impairment in Alzheimer's disease results in
considerable part from synaptic dysfunction caused by the accumulation of a range of …
considerable part from synaptic dysfunction caused by the accumulation of a range of …
Synaptic impairment in Alzheimer's disease: a dysregulated symphony
Alzheimer's disease (AD) is characterized by memory loss, cognitive decline, and
devastating neurodegeneration, not only as a result of the extracellular accumulation of beta …
devastating neurodegeneration, not only as a result of the extracellular accumulation of beta …
Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q
Microglia-mediated synaptic loss contributes to the development of cognitive impairments in
Alzheimer's disease (AD). However, the basis for this immune-mediated attack on synapses …
Alzheimer's disease (AD). However, the basis for this immune-mediated attack on synapses …
Interactions of pathological proteins in neurodegenerative diseases
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal lobar
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …
Prions, prionoids and protein misfolding disorders
C Scheckel, A Aguzzi - Nature Reviews Genetics, 2018 - nature.com
Prion diseases are progressive, incurable and fatal neurodegenerative conditions. The term
'prion'was first nominated to express the revolutionary concept that a protein could be …
'prion'was first nominated to express the revolutionary concept that a protein could be …
Amyloid β protein and Alzheimer's disease: When computer simulations complement experimental studies
J Nasica-Labouze, PH Nguyen, F Sterpone… - Chemical …, 2015 - ACS Publications
Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …
Large soluble oligomers of amyloid β-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate
Soluble oligomers of amyloid β-protein (oAβ) isolated from the brains of Alzheimer's disease
(AD) patients have been shown experimentally (in the absence of amyloid plaques) to …
(AD) patients have been shown experimentally (in the absence of amyloid plaques) to …
The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain
A Gasiorowska, M Wydrych, P Drapich… - Frontiers in aging …, 2021 - frontiersin.org
The elderly population is growing worldwide, with important health and socioeconomic
implications. Clinical and experimental studies on aging have uncovered numerous …
implications. Clinical and experimental studies on aging have uncovered numerous …
Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease
Alzheimer's disease (AD) is the most common form of dementia in the elderly, and affects
millions of people worldwide. As the number of AD cases continues to increase in both …
millions of people worldwide. As the number of AD cases continues to increase in both …